國家衛生研究院 NHRI:Item 3990099045/13857
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 851301      Online Users : 669
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13857


    Title: Survival outcomes of management in metastatic gastric adenocarcinoma patients
    Authors: Hu, HM;Tsai, HJ;Ku, HY;Lo, SS;Shan, YS;Chang, HC;Chao, Y;Chen, JS;Chen, SC;Chiang, CJ;Li, AF;Wang, HP;Wang, TE;Bai, LY;Wu, MS;Chen, LT;Liu, TW;Yang, YH
    Contributors: National Institute of Cancer Research
    Abstract: Chemotherapy is generally considered as the main treatment for metastatic gastric adenocarcinoma. The role of gastrectomy for metastatic gastric cancer without obvious symptoms is controversial. The objective of this study is to investigate survival outcomes of treatment modalities using a real-world data setting. A retrospective cohort study was designed using the Taiwan Cancer Registry database. We identified the treatment modalities and used Kaplan-Meier estimates and Cox regressions to compare patient survival outcomes. From 2008 to 2015, 5599 gastric adenocarcinoma patients were diagnosed with metastatic disease (M1). The median overall survival (OS) of patients with surgery plus chemotherapy had the longest survival of 14.2 months. The median OS of the patients who received chemotherapy alone or surgery alone was 7.0 and 3.9, respectively. Age at diagnosis, year of diagnosis, tumor grade, and treatment modalities are prognostic factors for survival. The hazard ratios for patients who received surgery plus chemotherapy, surgery alone, and supportive care were 0.47 (95% CI 0.44-0.51), 1.22 (95% CI 1.1-1.36), and 3.23 (95% CI 3.01-3.46), respectively, by multivariable Cox regression analysis when using chemotherapy alone as a referent. Chemotherapy plus surgery may have a survival benefit for some selected gastric adenocarcinoma patients with metastatic disease.
    Date: 2021-11-30
    Relation: Scientific Reports. 2021 Nov 30;11:Article number 23142.
    Link to: http://dx.doi.org/10.1038/s41598-021-02391-z
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2045-2322&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000724479000024
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85120177324
    Appears in Collections:[Yi-Hsin Yang] Periodical Articles
    [Li-Tzong Chen] Periodical Articles
    [Tsang-Wu Liu] Periodical Articles
    [Hui-Jen Tsai] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB34848751.pdf924KbAdobe PDF674View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback